A clinical study to compare the effects of Bhunimbadi and Triphala tablets as an add-on medication on HOMA-IR in Metabolic syndrome

Efficacy of Bhunimbadi tablet as an add-on medication on HOMA-IR in metabolic syndrome a randomized controlled trial - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/081555

Enrollment

Registered

2025-03-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E888- Other specified metabolic disorders

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Participants identified with MetS according to Harmonized criteria 2009 any three of the following Central obesity Waist Circumference greater than 90cmin males and greater than 80 cm in females Triglycerides greater than 1.7 mmol per litre or under medication HDL cholesterol less than 1.0 mmol per litre in males and less than 1.3 mmol per litre in females or under medication Blood pressure greater than 135/85 mmHg or under medication Fasting plasma glucose: greater than or equal to 100 mg/dL or under medication

Exclusion criteria

Exclusion criteria: Participants suffering from diagnosed case of chronic renal diseases Pregnant and lactating mothers HbA1c greater than 9% BMI greater than or equal to 35 kg/m 2

Design outcomes

Primary

Measure	Time frame
Homeostasis model assessment for insulin resistance (HOMA-IR)Timepoint: baseline, 90th day	—

Secondary

Measure	Time frame
Waist circumference HbA1c LFT TG HDL LDL SBP and DBP BMITimepoint: baseline, 90th day	—

Countries

India

Contacts

Public ContactDr Indulekha V C

Govt.Ayurveda College Thiruvananthapuram

drindulekha@gmail.com9446553068

Outcome results